Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

BACKGROUND: Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Duparc, Stephan, Chalon, Stephan, Miller, Scott, Richardson, Naomi, Toovey, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071640/
https://www.ncbi.nlm.nih.gov/pubmed/32169086
http://dx.doi.org/10.1186/s12936-020-03184-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071640/
https://www.ncbi.nlm.nih.gov/pubmed/32169086
http://dx.doi.org/10.1186/s12936-020-03184-x

Ejemplares similares